Fischer Medical Ventures Limited has informed the Exchange about General Updates
FISCHER · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Fischer Medical Ventures announced its unaudited Q1 FY26 (quarter ended 30 June 2025) results on 14 August 2025. On a standalone basis, revenue from operations fell to ₹454.23 lakhs from ₹521.97 lakhs in the previous quarter, and the company posted a net loss of ₹60.94 lakhs (EPS of ₹(0.09)). On a consolidated basis, revenue stood at ₹1,152.83 lakhs and net profit was ₹40.28 lakhs (EPS of ₹0.36). The Board fixed the 32nd Annual General Meeting for 29 September 2025 via video conferencing, with the share transfer books closed from 23 to 29 September 2025. M/s Nuren Lodaya & Associates was appointed as Scrutinizer and recommended as Secretarial Auditor for five years. Independent Director Dr. Jacob Thomas resigned from the Board effective end of day 14 August 2025, citing personal reasons.
Standalone operations remain in the red with declining revenue and a wider quarterly loss, which may pressure sentiment despite a modest consolidated profit. The resignation of an independent director and AGM-related book closure are routine compliance items, but investors should watch for further deterioration in the standalone business before the AGM.